Annals of Hematology

, Volume 93, Issue 12, pp 1953–1963 | Cite as

Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncology (ÖGHO) and Society of Thrombosis and Haemostasis Research (GTH e.V.)

  • Stephan Kreher
  • Sebastian Ochsenreither
  • Ralf U. Trappe
  • Ingrid Pabinger
  • Frauke Bergmann
  • Petro E. Petrides
  • Steffen Koschmieder
  • Axel Matzdorff
  • Andreas Tiede
  • Martin Griesshammer
  • Hanno Riess
Review Article


Patients with Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) like polycythemia vera and essential thrombocythemia are at increased risk of arterial and venous thrombosis. Strategies of prevention may consist of platelet aggregation inhibitors and/or cytoreductive agents depending on the underlying disease and the individual risk. Clinical evidence for management of acute venous thromboembolic events in MPN patients is limited. Modality and duration of therapeutic anticoagulation after venous thrombosis has to be evaluated critically with special regard to the increased risk for spontaneous bleeding events associated with the underlying diseases. Both for therapy of the acute event and for secondary prophylaxis, low-molecular-weight heparins should preferentially be used. A prolongation of the therapeutic anticoagulation beyond the usual 3 to 6 months can only be recommended in high-risk settings and after careful evaluation of potential risks and benefits for the individual patient. New direct oral anticoagulants (NOAC) should not preferentially be used due to lack of clinical experience in patients with MPN and potential drug interactions (e.g. with JAK inhibitors). Consequent treatment of the underlying myeloproliferative disease and periodical evaluation of the response to therapy is crucial for optimal secondary prophylaxis of thromboembolic events in those patients.


Venous thromboembolism Myeloproliferative neoplasm Essential thrombocythemia Polycythemia vera 


Authorship and disclosures

All authors contributed and approved the report.

Conflict of interest

The authors report no potential conflicts of interest.


  1. 1.
    Swerdlow SHCE, Harris NL et al (2008) WHO classification of tumours of haemopoietic and lymphoid tissues. IARC Press, Lyon, FranceGoogle Scholar
  2. 2.
    Murphy S, Peterson P, Iland H, Laszlo J (1997) Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 34(1):29–39PubMedGoogle Scholar
  3. 3.
    Johansson P (2006) Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia. Semin Thromb Hemost 32(3):171–173. doi: 10.1055/s-2006-939430 PubMedCrossRefGoogle Scholar
  4. 4.
    Jensen MK, de Nully Brown P, Nielsen OJ, Hasselbalch HC (2000) Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area. Eur J Haematol 65(2):132–139PubMedCrossRefGoogle Scholar
  5. 5.
    Mehta J, Wang H, Iqbal SU, Mesa R (2013) Epidemiology of myeloproliferative neoplasms (MPN) in the United States. Leuk Lymphoma. doi: 10.3109/10428194.2013.813500 PubMedGoogle Scholar
  6. 6.
    Tefferi A (2000) Myelofibrosis with myeloid metaplasia. N Engl J Med 342(17):1255–1265. doi: 10.1056/NEJM200004273421706 PubMedCrossRefGoogle Scholar
  7. 7.
    Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, Them NC, Berg T, Gisslinger B, Pietra D, Chen D, Vladimer GI, Bagienski K, Milanesi C, Casetti IC, Sant'Antonio E, Ferretti V, Elena C, Schischlik F, Cleary C, Six M, Schalling M, Schonegger A, Bock C, Malcovati L, Pascutto C, Superti-Furga G, Cazzola M, Kralovics R (2013) Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 369(25):2379–2390. doi: 10.1056/NEJMoa1311347 PubMedCrossRefGoogle Scholar
  8. 8.
    Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, Hehlmann R, Hoffman R, Kiladjian JJ, Kroger N, Mesa R, McMullin MF, Pardanani A, Passamonti F, Vannucchi AM, Reiter A, Silver RT, Verstovsek S, Tefferi A (2011) Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 29(6):761–770. doi: 10.1200/JCO.2010.31.8436 PubMedCrossRefGoogle Scholar
  9. 9.
    Shih AH, Abdel-Wahab O, Patel JP, Levine RL (2012) The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer 12(9):599–612. doi: 10.1038/nrc3343 PubMedCrossRefGoogle Scholar
  10. 10.
    Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365(9464):1054–1061. doi: 10.1016/S0140-6736(05)71142-9 PubMedCrossRefGoogle Scholar
  11. 11.
    James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, Garcon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, Casadevall N, Vainchenker W (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434(7037):1144–1148. doi: 10.1038/nature03546 PubMedCrossRefGoogle Scholar
  12. 12.
    Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D'Andrea A, Frohling S, Dohner K, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WR, Meyerson M, Golub TR, Lee SJ, Gilliland DG (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7(4):387–397. doi: 10.1016/j.ccr.2005.03.023 PubMedCrossRefGoogle Scholar
  13. 13.
    Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, Steensma DP, Elliott MA, Wolanskyj AP, Hogan WJ, McClure RF, Litzow MR, Gilliland DG, Tefferi A (2006) MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 108(10):3472–3476. doi: 10.1182/blood-2006-04-018879 PubMedCrossRefGoogle Scholar
  14. 14.
    Vannucchi AM, Antonioli E, Guglielmelli P, Pancrazzi A, Guerini V, Barosi G, Ruggeri M, Specchia G, Lo-Coco F, Delaini F, Villani L, Finotto S, Ammatuna E, Alterini R, Carrai V, Capaccioli G, Di Lollo S, Liso V, Rambaldi A, Bosi A, Barbui T (2008) Characteristics and clinical correlates of MPL 515W > L/K mutation in essential thrombocythemia. Blood 112(3):844–847. doi: 10.1182/blood-2008-01-135897 PubMedCrossRefGoogle Scholar
  15. 15.
    Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT, Duffy A, Boyd EM, Bench AJ, Scott MA, Vassiliou GS, Milligan DW, Smith SR, Erber WN, Bareford D, Wilkins BS, Reilly JT, Harrison CN, Green AR (2005) Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 366(9501):1945–1953. doi: 10.1016/S0140-6736(05)67785-9 PubMedCrossRefGoogle Scholar
  16. 16.
    Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, Avezov E, Li J, Kollmann K, Kent DG, Aziz A, Godfrey AL, Hinton J, Martincorena I, Van Loo P, Jones AV, Guglielmelli P, Tarpey P, Harding HP, Fitzpatrick JD, Goudie CT, Ortmann CA, Loughran SJ, Raine K, Jones DR, Butler AP, Teague JW, O'Meara S, McLaren S, Bianchi M, Silber Y, Dimitropoulou D, Bloxham D, Mudie L, Maddison M, Robinson B, Keohane C, Maclean C, Hill K, Orchard K, Tauro S, Du MQ, Greaves M, Bowen D, Huntly BJ, Harrison CN, Cross NC, Ron D, Vannucchi AM, Papaemmanuil E, Campbell PJ, Green AR (2013) Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 369(25):2391–2405. doi: 10.1056/NEJMoa1312542 PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, Marilus R, Villegas A, Tognoni G, Barbui T (2005) Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 23(10):2224–2232. doi: 10.1200/JCO.2005.07.062 PubMedCrossRefGoogle Scholar
  18. 18.
    Landolfi R, Di Gennaro L, Falanga A (2008) Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation. Leukemia 22(11):2020–2028. doi: 10.1038/leu.2008.253 PubMedCrossRefGoogle Scholar
  19. 19.
    Reikvam H, Tiu RV (2012) Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera. Leukemia 26(4):563–571. doi: 10.1038/leu.2011.314 PubMedCrossRefGoogle Scholar
  20. 20.
    Papadakis E, Hoffman R, Brenner B (2010) Thrombohemorrhagic complications of myeloproliferative disorders. Blood Rev 24(6):227–232. doi: 10.1016/j.blre.2010.08.002 PubMedCrossRefGoogle Scholar
  21. 21.
    McMullin MF, Bareford D, Campbell P, Green AR, Harrison C, Hunt B, Oscier D, Polkey MI, Reilly JT, Rosenthal E, Ryan K, Pearson TC, Wilkins B (2005) Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. Br J Haematol 130(2):174–195. doi: 10.1111/j.1365-2141.2005.05535.x PubMedCrossRefGoogle Scholar
  22. 22.
    Elliott MA, Tefferi A (2005) Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 128(3):275–290. doi: 10.1111/j.1365-2141.2004.05277.x PubMedCrossRefGoogle Scholar
  23. 23.
    Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A (2006) Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc 81(2):159–166. doi: 10.4065/81.2.159 PubMedCrossRefGoogle Scholar
  24. 24.
    Tefferi A (2012) Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 87(3):285–293. doi: 10.1002/ajh.23135 PubMedCrossRefGoogle Scholar
  25. 25.
    Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR (2005) Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 353(1):33–45. doi: 10.1056/NEJMoa043800 PubMedCrossRefGoogle Scholar
  26. 26.
    Casini A, Fontana P, Lecompte T (2013) Thrombotic complications of myeloproliferative neoplasms: risk assessment and risk-guided management. J Thromb Haemost. doi: 10.1111/jth.12265 PubMedGoogle Scholar
  27. 27.
    Barbui T, Carobbio A, Cervantes F, Vannucchi AM, Guglielmelli P, Antonioli E, Alvarez-Larran A, Rambaldi A, Finazzi G, Barosi G (2010) Thrombosis in primary myelofibrosis: incidence and risk factors. Blood 115(4):778–782. doi: 10.1182/blood-2009-08-238956 PubMedCrossRefGoogle Scholar
  28. 28.
    Tefferi A, Elliott M (2007) Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost 33(4):313–320. doi: 10.1055/s-2007-976165 PubMedCrossRefGoogle Scholar
  29. 29.
    De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E, Mico C, Tieghi A, Cacciola RR, Santoro C, Gerli G, Vianelli N, Guglielmelli P, Pieri L, Scognamiglio F, Rodeghiero F, Pogliani EM, Finazzi G, Gugliotta L, Marchioli R, Leone G, Barbui T (2008) Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica 93(3):372–380. doi: 10.3324/haematol.12053 PubMedCrossRefGoogle Scholar
  30. 30.
    Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, Randi ML, Vaidya R, Cazzola M, Rambaldi A, Gisslinger B, Pieri L, Ruggeri M, Bertozzi I, Sulai NH, Casetti I, Carobbio A, Jeryczynski G, Larson DR, Mullauer L, Pardanani A, Thiele J, Passamonti F, Barbui T (2013) Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. doi: 10.1038/leu.2013.163 Google Scholar
  31. 31.
    Kiladjian JJ, Cervantes F, Leebeek FW, Marzac C, Cassinat B, Chevret S, Cazals-Hatem D, Plessier A, Garcia-Pagan JC, Darwish Murad S, Raffa S, Janssen HL, Gardin C, Cereja S, Tonetti C, Giraudier S, Condat B, Casadevall N, Fenaux P, Valla DC (2008) The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood 111(10):4922–4929. doi: 10.1182/blood-2007-11-125328 PubMedCrossRefGoogle Scholar
  32. 32.
    Kurosawa H, Okuya M, Matsushita T, Kubota T, Endoh K, Kuwashima S, Hagisawa S, Sato Y, Fukushima K, Sugita K, Okada Y, Park MJ, Hayashi Y, Arisaka O (2009) JAK2V617F mutation-positive childhood essential thrombocythemia associated with cerebral venous sinus thrombosis. J Pediatr Hematol Oncol 31(9):678–680. doi: 10.1097/MPH.0b013e3181b1ec9e PubMedCrossRefGoogle Scholar
  33. 33.
    Anger BR, Seifried E, Scheppach J, Heimpel H (1989) Budd-Chiari syndrome and thrombosis of other abdominal vessels in the chronic myeloproliferative diseases. Klin Wochenschr 67(16):818–825PubMedCrossRefGoogle Scholar
  34. 34.
    Patel RK, Lea NC, Heneghan MA, Westwood NB, Milojkovic D, Thanigaikumar M, Yallop D, Arya R, Pagliuca A, Gaken J, Wendon J, Heaton ND, Mufti GJ (2006) Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology 130(7):2031–2038. doi: 10.1053/j.gastro.2006.04.008 PubMedCrossRefGoogle Scholar
  35. 35.
    Regina S, Herault O, D'Alteroche L, Binet C, Gruel Y (2007) JAK2 V617F is specifically associated with idiopathic splanchnic vein thrombosis. J Thromb Haemost 5(4):859–861. doi: 10.1111/j.1538-7836.2007.02384.x PubMedCrossRefGoogle Scholar
  36. 36.
    Boissinot M, Lippert E, Girodon F, Dobo I, Fouassier M, Masliah C, Praloran V, Hermouet S (2006) Latent myeloproliferative disorder revealed by the JAK2-V617F mutation and endogenous megakaryocytic colonies in patients with splanchnic vein thrombosis. Blood 108(9):3223–3224. doi: 10.1182/blood-2006-05-021527 PubMedCrossRefGoogle Scholar
  37. 37.
    Colaizzo D, Amitrano L, Tiscia GL, Scenna G, Grandone E, Guardascione MA, Brancaccio V, Margaglione M (2007) The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb Haemost 5(1):55–61. doi: 10.1111/j.1538-7836.2006.02277.x PubMedCrossRefGoogle Scholar
  38. 38.
    Chait Y, Condat B, Cazals-Hatem D, Rufat P, Atmani S, Chaoui D, Guilmin F, Kiladjian JJ, Plessier A, Denninger MH, Casadevall N, Valla D, Briere JB (2005) Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis. Br J Haematol 129(4):553–560. doi: 10.1111/j.1365-2141.2005.05490.x PubMedCrossRefGoogle Scholar
  39. 39.
    Briere JB (2006) Budd-Chiari syndrome and portal vein thrombosis associated with myeloproliferative disorders: diagnosis and management. Semin Thromb Hemost 32(3):208–218. doi: 10.1055/s-2006-939432 PubMedCrossRefGoogle Scholar
  40. 40.
    Smalberg JH, Arends LR, Valla DC, Kiladjian JJ, Janssen HL, Leebeek FW (2012) Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood 120(25):4921–4928. doi: 10.1182/blood-2011-09-376517 PubMedCrossRefGoogle Scholar
  41. 41.
    Primignani M, Barosi G, Bergamaschi G, Gianelli U, Fabris F, Reati R, Dell'Era A, Bucciarelli P, Mannucci PM (2006) Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology 44(6):1528–1534. doi: 10.1002/hep.21435 PubMedCrossRefGoogle Scholar
  42. 42.
    Falanga A, Marchetti M (2012) Thrombotic disease in the myeloproliferative neoplasms. Hematol Am Soc Hematol Educ Prog 2012:571–581. doi: 10.1182/asheducation-2012.1.571 Google Scholar
  43. 43.
    Jensen MK, de Nully Brown P, Lund BV, Nielsen OJ, Hasselbalch HC (2000) Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders. Br J Haematol 110(1):116–124PubMedCrossRefGoogle Scholar
  44. 44.
    Falanga A, Marchetti M, Evangelista V, Vignoli A, Licini M, Balicco M, Manarini S, Finazzi G, Cerletti C, Barbui T (2000) Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood 96(13):4261–4266PubMedGoogle Scholar
  45. 45.
    Falanga A, Marchetti M, Barbui T, Smith CW (2005) Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera: the role of neutrophils. Semin Hematol 42(4):239–247. doi: 10.1053/j.seminhematol.2005.05.023 PubMedCrossRefGoogle Scholar
  46. 46.
    Falanga A, Marchetti M, Vignoli A, Balducci D, Barbui T (2005) Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol 33(5):523–530. doi: 10.1016/j.exphem.2005.01.015 PubMedCrossRefGoogle Scholar
  47. 47.
    Barbui T, Carobbio A, Rambaldi A, Finazzi G (2009) Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor? Blood 114(4):759–763. doi: 10.1182/blood-2009-02-206797 PubMedCentralPubMedGoogle Scholar
  48. 48.
    Marchetti M, Castoldi E, Spronk HM, van Oerle R, Balducci D, Barbui T, Rosing J, Ten Cate H, Falanga A (2008) Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. Blood 112(10):4061–4068. doi: 10.1182/blood-2008-06-164087 PubMedCrossRefGoogle Scholar
  49. 49.
    Wautier MP, El Nemer W, Gane P, Rain JD, Cartron JP, Colin Y, Le Van Kim C, Wautier JL (2007) Increased adhesion to endothelial cells of erythrocytes from patients with polycythemia vera is mediated by laminin alpha5 chain and Lu/BCAM. Blood 110(3):894–901. doi: 10.1182/blood-2006-10-048298 PubMedCrossRefGoogle Scholar
  50. 50.
    Adams BD, Baker R, Lopez JA, Spencer S (2010) Myeloproliferative disorders and the hyperviscosity syndrome. Hematol Oncol Clin North Am 24(3):585–602. doi: 10.1016/j.hoc.2010.03.004 PubMedCrossRefGoogle Scholar
  51. 51.
    Rosti V, Villani L, Riboni R, Poletto V, Bonetti E, Tozzi L, Bergamaschi G, Catarsi P, Dallera E, Novara F, Massa M, Campanelli R, Fois G, Peruzzi B, Lucioni M, Guglielmelli P, Pancrazzi A, Fiandrino G, Zuffardi O, Magrini U, Paulli M, Vannucchi AM, Barosi G (2013) Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation. Blood 121(2):360–368. doi: 10.1182/blood-2012-01-404889 PubMedCrossRefGoogle Scholar
  52. 52.
    Duchemin J, Ugo V, Ianotto JC, Lecucq L, Mercier B, Abgrall JF (2010) Increased circulating procoagulant activity and thrombin generation in patients with myeloproliferative neoplasms. Thromb Res 126(3):238–242. doi: 10.1016/j.thromres.2010.06.025 PubMedCrossRefGoogle Scholar
  53. 53.
    Bucalossi A, Marotta G, Bigazzi C, Galieni P, Dispensa E (1996) Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis. Am J Hematol 52(1):14–20. doi: 10.1002/(SICI)1096-8652(199605)52:1<14::AID-AJH3>3.0.CO;2-9 PubMedCrossRefGoogle Scholar
  54. 54.
    Falanga A, Marchetti M, Vignoli A, Balducci D, Russo L, Guerini V, Barbui T (2007) V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules. Exp Hematol 35(5):702–711PubMedCrossRefGoogle Scholar
  55. 55.
    Cella G, Marchetti M, Vianello F, Panova-Noeva M, Vignoli A, Russo L, Barbui T, Falanga A (2010) Nitric oxide derivatives and soluble plasma selectins in patients with myeloproliferative neoplasms. Thromb Haemost 104(1):151–156. doi: 10.1160/TH09-09-0663 PubMedCrossRefGoogle Scholar
  56. 56.
    Karakantza M, Giannakoulas NC, Zikos P, Sakellaropoulos G, Kouraklis A, Aktypi A, Metallinos IC, Theodori E, Zoumbos NC, Maniatis A (2004) Markers of endothelial and in vivo platelet activation in patients with essential thrombocythemia and polycythemia vera. Int J Hematol 79(3):253–259PubMedCrossRefGoogle Scholar
  57. 57.
    Barbui T, Carobbio A, Finazzi G, Vannucchi AM, Barosi G, Antonioli E, Guglielmelli P, Pancrazzi A, Salmoiraghi S, Zilio P, Ottomano C, Marchioli R, Cuccovillo I, Bottazzi B, Mantovani A, Rambaldi A (2011) Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. Haematologica 96(2):315–318. doi: 10.3324/haematol.2010.031070 PubMedCentralPubMedCrossRefGoogle Scholar
  58. 58.
    Federici AB, Rand JH, Bucciarelli P, Budde U, van Genderen PJ, Mohri H, Meyer D, Rodeghiero F, Sadler JE (2000) Acquired von Willebrand syndrome: data from an international registry. Thromb Haemost 84(2):345–349PubMedGoogle Scholar
  59. 59.
    van Genderen PJ, Leenknegt H, Michiels JJ, Budde U (1996) Acquired von Willebrand disease in myeloproliferative disorders. Leuk Lymphoma 22(Suppl 1):79–82. doi: 10.3109/10428199609074364 PubMedCrossRefGoogle Scholar
  60. 60.
    Tefferi A, Gangat N, Wolanskyj AP (2006) Management of extreme thrombocytosis in otherwise low-risk essential thrombocythemia; does number matter? Blood 108(7):2493–2494. doi: 10.1182/blood-2006-05-025544 PubMedCrossRefGoogle Scholar
  61. 61.
    Michiels JJ, Berneman Z, Schroyens W, Finazzi G, Budde U, van Vliet HH (2006) The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera. Semin Thromb Hemost 32(6):589–604. doi: 10.1055/s-2006-949664 PubMedCrossRefGoogle Scholar
  62. 62.
    Marchioli R, Finazzi G, Specchia G, Masciulli A, Mennitto MR, Barbui T (2011) The CYTO-PV: a large-scale trial testing the intensity of cytoreductive therapy to prevent cardiovascular events in patients with polycythemia vera. Thromb 2011:794240. doi: 10.1155/2011/794240 CrossRefGoogle Scholar
  63. 63.
    Radaelli F, Colombi M, Calori R, Zilioli VR, Bramanti S, Iurlo A, Zanella A (2007) Analysis of risk factors predicting thrombotic and/or haemorrhagic complications in 306 patients with essential thrombocythemia. Hematol Oncol 25(3):115–120. doi: 10.1002/hon.816 PubMedCrossRefGoogle Scholar
  64. 64.
    Besses C, Cervantes F, Pereira A, Florensa L, Sole F, Hernandez-Boluda JC, Woessner S, Sans-Sabrafen J, Rozman C, Montserrat E (1999) Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukemia 13(2):150–154PubMedCrossRefGoogle Scholar
  65. 65.
    Carobbio A, Finazzi G, Guerini V, Spinelli O, Delaini F, Marchioli R, Borrelli G, Rambaldi A, Barbui T (2007) Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood 109(6):2310–2313. doi: 10.1182/blood-2006-09-046342 PubMedCrossRefGoogle Scholar
  66. 66.
    Landolfi R, Di Gennaro L, Barbui T, De Stefano V, Finazzi G, Marfisi R, Tognoni G, Marchioli R (2007) Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood 109(6):2446–2452. doi: 10.1182/blood-2006-08-042515 PubMedCrossRefGoogle Scholar
  67. 67.
    Palandri F, Polverelli N, Catani L, Ottaviani E, Baccarani M, Vianelli N (2012) Very elderly patients with essential thrombocythaemia: are they a separate category? A monocentric study on 118 patients older than 75 years. Br J Haematol 156(5):676–679. doi: 10.1111/j.1365-2141.2011.08903.x PubMedCrossRefGoogle Scholar
  68. 68.
    Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, De Stefano V, Elli E, Iurlo A, Latagliata R, Lunghi F, Lunghi M, Marfisi RM, Musto P, Masciulli A, Musolino C, Cascavilla N, Quarta G, Randi ML, Rapezzi D, Ruggeri M, Rumi E, Scortechini AR, Santini S, Scarano M, Siragusa S, Spadea A, Tieghi A, Angelucci E, Visani G, Vannucchi AM, Barbui T (2013) Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 368(1):22–33. doi: 10.1056/NEJMoa1208500 PubMedCrossRefGoogle Scholar
  69. 69.
    Vannucchi AM, Antonioli E, Guglielmelli P, Rambaldi A, Barosi G, Marchioli R, Marfisi RM, Finazzi G, Guerini V, Fabris F, Randi ML, De Stefano V, Caberlon S, Tafuri A, Ruggeri M, Specchia G, Liso V, Rossi E, Pogliani E, Gugliotta L, Bosi A, Barbui T (2007) Clinical profile of homozygous JAK2 617V > F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 110(3):840–846. doi: 10.1182/blood-2006-12-064287 PubMedCrossRefGoogle Scholar
  70. 70.
    Dahabreh IJ, Zoi K, Giannouli S, Zoi C, Loukopoulos D, Voulgarelis M (2009) Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia. Leuk Res 33(1):67–73. doi: 10.1016/j.leukres.2008.06.006 PubMedCrossRefGoogle Scholar
  71. 71.
    Vannucchi AM, Antonioli E, Guglielmelli P, Longo G, Pancrazzi A, Ponziani V, Bogani C, Ferrini PR, Rambaldi A, Guerini V, Bosi A, Barbui T (2007) Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia 21(9):1952–1959. doi: 10.1038/sj.leu.2404854 PubMedCrossRefGoogle Scholar
  72. 72.
    Carobbio A, Finazzi G, Antonioli E, Guglielmelli P, Vannucchi AM, Dellacasa CM, Salmoiraghi S, Delaini F, Rambaldi A, Barbui T (2009) JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera. Exp Hematol 37(9):1016–1021. doi: 10.1016/j.exphem.2009.06.006 PubMedCentralPubMedCrossRefGoogle Scholar
  73. 73.
    Tefferi A, Lasho TL, Schwager SM, Strand JS, Elliott M, Mesa R, Li CY, Wadleigh M, Lee SJ, Gilliland DG (2006) The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer 106(3):631–635. doi: 10.1002/cncr.21645 PubMedCrossRefGoogle Scholar
  74. 74.
    Gangat N, Strand J, Li CY, Wu W, Pardanani A, Tefferi A (2007) Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation. Br J Haematol 138(3):354–358. doi: 10.1111/j.1365-2141.2007.06674.x PubMedCrossRefGoogle Scholar
  75. 75.
    Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, Milosevic JD, Them NC, Berg T, Elena C, Casetti IC, Milanesi C, Sant'antonio E, Bellini M, Fugazza E, Renna MC, Boveri E, Astori C, Pascutto C, Kralovics R, Cazzola M (2013) JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. doi: 10.1182/blood-2013-11-539098 PubMedCentralGoogle Scholar
  76. 76.
    Rotunno G, Mannarelli C, Guglielmelli P, Pacilli A, Pancrazzi A, Pieri L, Fanelli T, Bosi A, Vannucchi A (2013) Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood. doi: 10.1182/blood-2013-11-538983 PubMedCentralGoogle Scholar
  77. 77.
    Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Vannucchi AM, Antonioli E, Gisslinger H, Buxhofer-Ausch V, Finazzi G, Gangat N, Tefferi A, Barbui T (2011) Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood 117(22):5857–5859. doi: 10.1182/blood-2011-02-339002 PubMedCrossRefGoogle Scholar
  78. 78.
    Ruggeri M, Gisslinger H, Tosetto A, Rintelen C, Mannhalter C, Pabinger I, Heis N, Castaman G, Missiaglia E, Lechner K, Rodeghiero F (2002) Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia. Am J Hematol 71(1):1–6. doi: 10.1002/ajh.10153 PubMedCrossRefGoogle Scholar
  79. 79.
    Barbui T (2011) How to manage thrombosis in myeloproliferative neoplasms. Curr Opin Oncol 23(6):654–658. doi: 10.1097/CCO.0b013e32834bb867 PubMedCrossRefGoogle Scholar
  80. 80.
    Landolfi R, Di Gennaro L (2008) Prevention of thrombosis in polycythemia vera and essential thrombocythemia. Haematologica 93(3):331–335. doi: 10.3324/haematol.12604 PubMedCrossRefGoogle Scholar
  81. 81.
    (1981) Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomized trial. “Leukemia and Hematosarcoma” Cooperative Group, European Organization for Research on Treatment of Cancer (E.O.R.T.C.). Br J Cancer 44 (1):75–80Google Scholar
  82. 82.
    Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, Barbui T (2004) Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 350(2):114–124. doi: 10.1056/NEJMoa035572 PubMedCrossRefGoogle Scholar
  83. 83.
    Alvarez-Larran A, Cervantes F, Pereira A, Arellano-Rodrigo E, Perez-Andreu V, Hernandez-Boluda JC, Ayats R, Salvador C, Muntanola A, Bellosillo B, Vicente V, Hernandez-Nieto L, Burgaleta C, Xicoy B, Besses C (2010) Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood 116(8):1205–1210. doi: 10.1182/blood-2010-01-263319, quiz 1387PubMedCrossRefGoogle Scholar
  84. 84.
    Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, Barbui T (1995) Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 332(17):1132–1136. doi: 10.1056/NEJM199504273321704 PubMedCrossRefGoogle Scholar
  85. 85.
    Alvarez-Larran A, Pereira A, Arellano-Rodrigo E, Hernandez-Boluda JC, Cervantes F, Besses C (2013) Cytoreduction plus low-dose aspirin versus cytoreduction alone as primary prophylaxis of thrombosis in patients with high-risk essential thrombocythaemia: an observational study. Br J Haematol. doi: 10.1111/bjh.12321 Google Scholar
  86. 86.
    Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, Kralovics R, Petrides PE (2013) Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET study, a randomized controlled trial. Blood 121(10):1720–1728. doi: 10.1182/blood-2012-07-443770 PubMedCentralPubMedCrossRefGoogle Scholar
  87. 87.
    Verstovsek S, Kiladjian J, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison C, Pane F, Zachee P, Mesa R, He S, Jones M, Garrett W, Li J, Pirron U, Lawniczek T, Vannucchi A (2014) J Clin Oncol 32:5s, (suppl; abstr 7026)Google Scholar
  88. 88.
    Harrison C (2005) Pregnancy and its management in the Philadelphia negative myeloproliferative diseases. Br J Haematol 129(3):293–306. doi: 10.1111/j.1365-2141.2005.05400.x PubMedCrossRefGoogle Scholar
  89. 89.
    Ruggeri M, Rodeghiero F, Tosetto A, Castaman G, Scognamiglio F, Finazzi G, Delaini F, Mico C, Vannucchi AM, Antonioli E, De Stefano V, Za T, Gugliotta L, Tieghi A, Mazzucconi MG, Santoro C, Barbui T (2008) Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey. Blood 111(2):666–671. doi: 10.1182/blood-2007-07-102665 PubMedCrossRefGoogle Scholar
  90. 90.
    Barbui T, Barosi G, Grossi A, Gugliotta L, Liberato LN, Marchetti M, Mazzucconi MG, Rodeghiero F, Tura S (2004) Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 89(2):215–232PubMedGoogle Scholar
  91. 91.
    Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuunemann HJ (2012) Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):7S–47S. doi: 10.1378/chest.1412S3 PubMedCentralPubMedCrossRefGoogle Scholar
  92. 92.
    Interdisziplinäre S2-Leitlinie: Diagnostik und Therapie der Venenthrombose und der Lungenembolie (2010) Eur J Vasc Med 39 · S/78Google Scholar
  93. 93.
    Spectre G, Kalish Y, Schliamser L, Varon D (2008) Heparin-induced thrombocytopenia in myeloproliferative disorders: a rare or under-diagnosed complication? Am J Hematol 83(5):420–423. doi: 10.1002/ajh.21128 PubMedCrossRefGoogle Scholar
  94. 94.
    Randi ML, Tezza F, Scapin M, Duner E, Scarparo P, Scandellari R, Fabris F (2010) Heparin-induced thrombocytopenia in patients with Philadelphia-negative myeloproliferative disorders and unusual splanchnic or cerebral vein thrombosis. Acta Haematol 123(3):140–145. doi: 10.1159/000280466 PubMedCrossRefGoogle Scholar
  95. 95.
    van der Heijden JF, Hutten BA, Buller HR, Prins MH (2002) Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism. Cochrane Database Syst Rev 1, CD002001. doi: 10.1002/14651858.CD002001 PubMedGoogle Scholar
  96. 96.
    Hull RD, Pineo GF, Brant RF, Mah AF, Burke N, Dear R, Wong T, Cook R, Solymoss S, Poon MC, Raskob G (2006) Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 119(12):1062–1072. doi: 10.1016/j.amjmed.2006.02.022 PubMedCrossRefGoogle Scholar
  97. 97.
    Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349(2):146–153. doi: 10.1056/NEJMoa025313 PubMedCrossRefGoogle Scholar
  98. 98.
    Andras A, Sala Tenna A, Crawford F (2012) Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism. Cochrane Database Syst Rev 10, CD002001. doi: 10.1002/14651858.CD002001.pub2 PubMedGoogle Scholar
  99. 99.
    Schulman S, Beyth RJ, Kearon C, Levine MN (2008) Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133(6 Suppl):257S–298S. doi: 10.1378/chest.08-0674 PubMedCrossRefGoogle Scholar
  100. 100.
    Hoekstra J, Bresser EL, Smalberg JH, Spaander MC, Leebeek FW, Janssen HL (2011) Long-term follow-up of patients with portal vein thrombosis and myeloproliferative neoplasms. J Thromb Haemost 9(11):2208–2214. doi: 10.1111/j.1538-7836.2011.04484.x PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Stephan Kreher
    • 1
  • Sebastian Ochsenreither
    • 1
  • Ralf U. Trappe
    • 2
  • Ingrid Pabinger
    • 3
  • Frauke Bergmann
    • 4
  • Petro E. Petrides
    • 5
  • Steffen Koschmieder
    • 6
  • Axel Matzdorff
    • 7
  • Andreas Tiede
    • 8
  • Martin Griesshammer
    • 9
  • Hanno Riess
    • 1
  1. 1.Department of Hematology and OncologyCharite BerlinBerlinGermany
  2. 2.Department of Hematology and Oncology, DIAKOEv. Diakonie-Krankenhaus GmbHBremenGermany
  3. 3.Clinical Department for Hematology and HemostaseologyVienna General Hospital–University ClinicViennaAustria
  4. 4.MVZ Wagnerstibbe Für Laboratoriumsmedizin Und Pathologie GmbHHannoverGermany
  5. 5.Hematology Oncology CenterMunich IsartorMunichGermany
  6. 6.Department of Hematology, Oncology and Stem Cell TransplantationUniversity Hospital RWTH AachenAachenGermany
  7. 7.Department of Hematology and OncologyCaritas Klinikum SaarbrückenSaarbrückenGermany
  8. 8.Department for Hematology, Hemostaseology, Oncology and Stem Cell TransplantationHannover Medical SchoolHannoverGermany
  9. 9.Department of Hematology, Oncology and Palliative CareMühlenkreiskliniken Johannes Wesling Klinikum MindenMindenGermany

Personalised recommendations